Figure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy

<p>Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.</p>